针刺治疗肠易激综合征病例注册登记研究

注册号:

Registration number:

ITMCTR2100005328

最近更新日期:

Date of Last Refreshed on:

2021-04-12

注册时间:

Date of Registration:

2021-04-12

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺治疗肠易激综合征病例注册登记研究

Public title:

A case registration study of acupuncture treatment of irritable bowel syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗肠易激综合征病例注册登记研究

Scientific title:

A case registration study of acupuncture treatment of irritable bowel syndrome

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100045329 ; ChiMCTR2100005328

申请注册联系人:

叶坤

研究负责人:

陈敏

Applicant:

Ye Kun

Study leader:

Chen Min

申请注册联系人电话:

Applicant telephone:

+86 18482135491

研究负责人电话:

Study leader's telephone:

+86 28 87765705

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yekun@stu.cdutcm.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

cm@cdutcm.edu.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市金牛区十二桥路37号

研究负责人通讯地址:

四川省成都市金牛区十二桥路39号

Applicant address:

37 Sherqiao Road, Jinniu District, Chengdu, Sichuan

Study leader's address:

39 Sherqiao Road, Jinniu District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都中医药大学

Applicant's institution:

Chengdu University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2021KL-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

成都中医药大学附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, Hospital of Chengdu University of TCM

伦理委员会批准日期:

Date of approved by ethic committee:

2021/2/2 0:00:00

伦理委员会联系人:

马喜桃

Contact Name of the ethic committee:

Ma Xitao

伦理委员会联系地址:

四川省成都市金牛区十二桥路39号

Contact Address of the ethic committee:

39 Sherqiao Road, Jinniu District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都中医药大学

Primary sponsor:

Chengdu University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

四川省成都市金牛区十二桥路37号

Primary sponsor's address:

37 Sherqiao Road, Jinniu District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

具体地址:

金牛区十二桥路39号

Institution
hospital:

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Address:

39 Sherqiao Road, Jinniu District

经费或物资来源:

国家重点研发计划

Source(s) of funding:

National Key R&D Program of China

研究疾病:

肠易激综合征

研究疾病代码:

Target disease:

irritable bowel syndrome

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

连续入组

Sequential

研究所处阶段:

Study phase:

其它

Others

研究目的:

1.建立基于网络的针刺治疗肠易激综合征的病例注册登记平台,确定平台的运行模式、语言版本、数据元素、数据来源等; 2.通过登记的针灸治疗肠易激综合征的临床病例,分析真实世界中针灸治疗肠易激综合征的基本诊疗情况,探究针刺治疗肠易激综合征临床疗效的影响因素,筛选治疗肠易激综合征的针灸优势治疗方案。

Objectives of Study:

1.Establish a network-based case registration platform for acupuncture treatment of irritable bowel syndrome, and determine the operation mode, language version, data elements and data sources of the platform, etc.; 2.Through the registered clinical cases of acupuncture in the treatment of irritable bowel syndrome, the basic diagnosis and treatment situation of acupuncture and moxibustion in the treatment of irritable bowel syndrome in the real world was analyzed, the influencing factors of the clinical efficacy of acupuncture in the treatment of irritable bowel syndrome were explored, and the advantageous treatment plan of acupuncture and moxibustion in the treatment of irritable bowel syndrome was screened.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.年龄>18岁者; 2.符合罗马IV诊断标准中IBS的诊断; 3.自愿参加本试验并签署知情同意书。 注:符合上述所有条件才进行纳入。

Inclusion criteria

1.Age>18 years old; 2.Meet the Roman IV diagnostic criteria for IBS; 3.Participate in the study voluntarily and sign the informed consent. Note: Inclusion will be required if all of the above conditions are met.

排除标准:

1.既往肠镜检查、餐钡透视、腹部超声等检查发现严重肠道器质性病变(包括包括但不限于溃疡性结肠炎、家族性多发性肠息肉、结直肠癌患者); 2.意识不清、不能表达主观不适症状者及明确诊断的严重精神障碍; 3.不愿意参与随访者。 注:凡符合上述任何1条的患者,均予以排除。

Exclusion criteria:

1.Previous colonoscopy, meal barium fluoroscopy, abdominal ultrasound and other examinations found severe intestinal organic lesions (including but not limited to ulcerative colitis, familial multiple intestinal polyps, colorectal cancer patients); 2.Unconscious, unable to express subjective symptoms of discomfort and clearly diagnosed severe mental disorders; 3.Unwilling to participate in the accompanying visitors. Note: Patients who meet any of the above criteria will be excluded.

研究实施时间:

Study execute time:

From 2021-04-15

To      2024-02-01

征募观察对象时间:

Recruiting time:

From 2021-04-15

To      2023-10-01

干预措施:

Interventions:

组别:

连续入组

样本量:

400

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

样本总量 Total sample size : 400

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

成都

市(区县):

Country:

China

Province:

Chengdu

City:

单位(医院):

四川省第二中医医院

单位级别:

三级甲等

Institution/hospital:

Sichuan Second Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

成都

市(区县):

Country:

China

Province:

Chengdu

City:

单位(医院):

成都中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

大便性状

指标类型:

次要指标

Outcome:

Stool property

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

排便次数

指标类型:

次要指标

Outcome:

Defecate frequency

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠易激综合征病情严重程度量表

指标类型:

主要指标

Outcome:

Irritable bowel syndrome symptom severity scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁自评量表

指标类型:

次要指标

Outcome:

Self-rating depression scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评量表

指标类型:

次要指标

Outcome:

Self-Rating Anxiety Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠易激综合征症状充分缓解评估

指标类型:

次要指标

Outcome:

Assessment of adequate remission of irritable bowel syndrome symptoms

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用。

Randomization Procedure (please state who generates the random number sequence and by what method):

Not applicable.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024年6月30日;电子邮箱。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

June 30, 2024, E-mail.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子采集和管理系统:病例记录表由研究人员及时采集和记录,并将完成的病例记录表及时存档;将完成研究的试验数据及时录入到电子采集和管理系统中,采取双录入的形式。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form and electronic collection and management system:The CRF shall be collected and recorded by the researcher in time, and the completed medical record sheet shall be filed in time;Timely input the test data completed in the study into the electronic collection and management system, in the form of double input.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统